314298-13-0

Basic information

• Product Name: Benzene,1-fluoro-5-methoxy-2-methyl-4-nitro-
• Synonyms: 1-Fluoro-2-methyl-5-(methyloxy)-4-nitrobenzene;5-Fluoro-4-methyl-2-nitrophenyl methyl ether
• CAS NO: 314298-13-0
• Molecular Formula: C₈H₈FNO₃
• Molecular Weight: 185.1524232
• Product Categories: METHOXY
• Mol File: 314298-13-0.mol

Chemical Properties

• Boiling Point: 272.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.270±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzene,1-fluoro-5-methoxy-2-methyl-4-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene,1-fluoro-5-methoxy-2-methyl-4-nitro-(314298-13-0)
• EPA Substance Registry System: Benzene,1-fluoro-5-methoxy-2-methyl-4-nitro-(314298-13-0)

Safety Data

• Hazardous Substances Data: 314298-13-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzene, 1-fluoro-5-methoxy-2-methyl-4-nitro-, is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications, making it a valuable component in medicinal chemistry.
Used in Agrochemical Production:
Benzene,1-fluoro-5-methoxy-2-methyl-4-nitroalso serves as a building block in the production of agrochemicals, contributing to the development of new pesticides and other agricultural products designed to improve crop yields and protect plants from pests.
Used in Pesticide Formulation (with restrictions):
Although its use as a pesticide has become more limited due to environmental and health concerns, Benzene, 1-fluoro-5-methoxy-2-methyl-4-nitro-, may still be utilized in the formulation of certain pesticides. Its inclusion in these products is carefully regulated to minimize potential risks.

Upstream product

• 106579-00-4 5-methoxy-2-methyl-4-nitroaniline 
• 452-78-8 3-fluoro-4-methyl phenol 
• 83341-28-0 5-fluoro-4-methyl-2-nitrophenol 
• 74-88-4 methyl iodide 

Downstream Products

• 314298-14-1 4-fluoro-2-methoxy-5-methyl-phenylamine 
• 314298-15-2 1-bromo-4-fluoro-2-methoxy-5-methyl-benzene 
• 314298-16-3 4-fluoro-2-methoxy-5-methyl-benzonitrile 
• 314298-17-4 4-fluoro-2-methoxy-5-methyl-benzoic acid 
• 314298-21-0 [2-(4-bromo-2-fluorobenzylthiocarbamoyl)-5-fluoro-4-methyl-phenoxy]-acetic acid ethyl ester 
• 1089280-88-5 Phenylmethyl 4-{1-[2-methyl-5-(methyloxy)-4-nitrophenyl]-4-piperidinyl}-1-piperazinecarboxylate 
• 1116230-14-8 1-isopropyl-4-(5-methoxy-2-methyl-4-nitrophenyl)piperazine 
• 1089281-65-1 1-[2-methyl-5-(methyloxy)-4-nitrophenyl]-4-[2-(methylsulfonyl)ethyl]piperazine 
• 1356962-93-0 8-(5-Methoxy-2-methyl-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 1356963-01-3 2-methoxy-5-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline 
• 1356962-90-7 1-(1-(5-methoxy-2-methyl-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine 
• 1356962-99-6 (R)-4-(3-fluoropyrrolidin-1-yl)-1-(5-methoxy-2-methyl-4-nitrophenyl)piperidine 
• 1356963-00-2 1-(5-methoxy-2-methyl-4-nitrophenyl)piperidin-4-one 
• 1116230-00-2 tert-butyl 4-(5-methoxy-2-methyl-4-nitrophenyl) piperazine-1-carboxylate 

Relevant articles and documents

Novel(1,2,4)triazolo(1,5-a)pyridylphosphine oxide and use thereof

The present invention relates to novel(1,2,4)triazolo(1,5-a)pyridinyl phosphorus oxides and uses thereof. Wherein the compound is a compound represented by a formula I, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a stereoisomer thereof, or a tautomer thereof, or a prodrug thereof, and R1 to R5 are as defined in the specification. The compound disclosed by the invention can be used for preparing a medicine for treating and/or preventing cancers.

Tyrosine Kinase Inhibitor And Uses Thereof

Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

CHEMICAL COMPOUNDS

The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the tr

THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents

2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER

Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Design and synthesis of highly potent and selective (2-arylcarbamoyl- phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid aldose reductase inhibitors. The compound class features a core template that utilizes an intramolecular hydrogen bond to position the key structural elements of the pharmacophore in a conformation, which promotes a high binding affinity. The lead candidate, example 40, 5-fluoro-2-(4-bromo-2-fluoro-benzylthiocarbamoyl)-phenoxyacetic acid, inhibits aldose reductase with an IC50 of 30 nM, while being 1100 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. In addition, example 40 lowers nerve sorbitol levels with an ED50 of 31 mg/kg/d po in the 4-day STZ-induced diabetic rat model.

Substituted phenoxyacetic acids

Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other therapeutic agents, and methods of treatment employing the compounds and pharmaceutical compositions, as well as methods for their synthesis.